1. Scrip
  2. >>Therapy Areas

Roche Gives The Stage To A New Generation Of Cancer Drugs

 
• By Jessica Merrill

With big oncology losses largely in the rearview mirror, Roche is trying to sell investors on its next wave of cancer drugs; R&D overview pushes message of pipeline renewal.

Stage Spotlight
Roche put a spotlight on its oncology growth opportunities • Source: Alamy

Roche Holding AG hopes to maintain long-term leadership in oncology as it shores up its cancer portfolio and pipeline. After losing market exclusivity on three top-selling oncology franchises – Avastin (bevacizumab), Rituxan (rituximab) and Herceptin (trastuzumab) – Roche is enthusiastic about rebuilding its portfolio and is ready to showcase its next generation of potential blockbuster cancer drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.